サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1385469

アジア太平洋の多重がん検査市場 - 分析と予測（2023年～2032年）

Asia-Pacific Multicancer Screening Market - Analysis and Forecast, 2023-2032

出版日
発行
BIS Research
ページ情報
英文 95 Pages
納期
1～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
アジア太平洋の多重がん検査市場 - 分析と予測（2023年～2032年）
出版日: 2023年11月24日
発行: BIS Research
ページ情報: 英文 95 Pages
納期: 1～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

2022年現在、アジア太平洋の多重がん検査の市場規模は2億7,000万米ドルと評価され、2032年には14億米ドルに達すると予測されています。

がん罹患率の上昇とリキッドバイオプシー検査の利用拡大が、アジア太平洋における多重がん検査市場の拡大を促進すると予測されます。

主要市場統計
予測期間 2023年～2032年
2023年評価 3億2,000万米ドル
2032年予測 14億米ドル
CAGR 17.6%

アジア太平洋（APAC）における多重がん検査市場は、同地域がヘルスケアインフラの改善と様々な悪性腫瘍の罹患率増加への対策に注力していることから、大きな発展が見込まれています。高度な診断技術によって多数のがん種を同時に検出する多重がん検査は、早期発見が治療成績向上に果たす重要な役割に対する認識が高まるにつれて、アジア太平洋でますます普及しています。同市場は、がん予防・制御のためのイニシアチブの増加、高齢化、スクリーニング技術の技術的飛躍的進歩に後押しされています。アジア太平洋の政府やヘルスケア機関が包括的ながん検診プログラムの導入を重視している結果、多重がん検査市場は成長しています。APACの多重がん検査市場は、より利用しやすく正確ながん診断への需要が高まるにつれて成長すると予想されます。

当レポートでは、アジア太平洋の多重がん検査市場について調査し、市場の概要とともに、国別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場

  • 製品の定義
  • 包含基準と除外基準
  • 市場範囲
  • 調査手法

第2章 市場概要

  • 市場概要
  • 多重がん検査のワークフロー分析
  • 市場のフットプリントと成長の可能性
  • 将来性
  • COVID-19による市場への影響

第3章 業界考察

  • 特許分析
  • 償還シナリオ
  • サプライチェーン分析
  • 価格分析（テストタイプ別）

第4章 市場力学

  • 概要
  • 影響分析
  • 市場の促進要因
  • 市場の課題
  • 市場の機会

第5章 競合情勢

  • 主要な戦略と展開
  • 市場シェア分析（2022年）
  • 成長シェア分析（2022年）

第6章 アジア太平洋

  • 概要
  • アジア太平洋

第7章 市場-企業プロファイル

  • 概要
  • 多重がん検査市場の市場バリューチェーン
  • 多重がん検査エコシステムの参入企業
  • Burning Rock DX
  • Genecast Biotechnology Co., Ltd
  • Konica Minolta, Inc. (Ambry Genetics.)
図表

List of Figures

  • Figure 1: Asia-Pacific Multicancer Screening Market, $Billion, 2022 and 2032
  • Figure 2: Share of Asia-Pacific Multicancer Screening Market (by Test Type), $Billion, 2021 and 2032
  • Figure 3: Share of Asia-Pacific Multicancer Screening Market (by Sample), $Billion, 2021 and 2032
  • Figure 4: Share of Asia-Pacific Multicancer Screening Market (by Cancer Type), $Billion, 2021 and 2032
  • Figure 5: Share of Multicancer Screening Market (by Region), 2022
  • Figure 6: Asia-Pacific Multicancer Screening Market Segmentation
  • Figure 7: Asia-Pacific Multicancer Screening Market: Research Methodology
  • Figure 8: Primary Research Methodology
  • Figure 9: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 10: Top-Down Approach (Segment-Wise Analysis)
  • Figure 11: Multicancer Screening Workflow, End User Perspective
  • Figure 12: Multicancer Screening Workflow, Laboratory Technician Perspective
  • Figure 13: Asia-Pacific Multicancer Screening Market, $Billion, 2021-2032
  • Figure 14: COVID-19 Impact
  • Figure 15: Asia-Pacific Multicancer Screening Market, Patent Analysis (by Year), January 2020-December 2022
  • Figure 16: Multicancer Screening Market, Patent Analysis (by Country), January 2020-December 2022
  • Figure 17: Multicancer Screening Market, Patent Analysis (by Region), January 2020-December 2022
  • Figure 18: Supply Chain Analysis of the Multicancer Screening Market
  • Figure 19: Asia-Pacific Multicancer Screening Market Dynamics
  • Figure 20: Prevalence vs. Age-Standardized Death Rate of Cancer Globally, 2010-2019 (%)
  • Figure 21: Liquid Biopsy vs. Tissue Biopsy
  • Figure 22: Liquid Biopsy Clinical Trials (by Cancer Types), Share (%), 2023
  • Figure 23: Out-of-Pocket Costs for Complete Treatment by Cancer Type and Stage Among Insured Patient, ($)
  • Figure 24: Lead-Time Bias in Cancer Screening
  • Figure 25: Screened vs. Non-Screened Cancer Patients per 1,000,000 Incidence Rate (50-79 Years)
  • Figure 26: Multicancer Early Detection Tests + Usual Care Screening Costs vs. only Usual Care Screening Costs
  • Figure 27: Share of Key Developments and Strategies, January 2020-January 2023
  • Figure 28: Synergistic Activities Share (by Company), January 2020- January 2023
  • Figure 29: Product Launches and Upgradations (by Company), January 2020-January 2023
  • Figure 30: Market Share Analysis for Asia-Pacific Multicancer Screening Market, $Billion, 2022
  • Figure 31: Growth-Share Analysis of the Asia-Pacific Multicancer Screening Market (by Technology), 2022
  • Figure 32: Multicancer Screening Market Snapshot (by Region), $Billion, 2022
  • Figure 33: Multicancer Screening Market (by Region), $Billion, 2021-2032
  • Figure 34: Asia-Pacific Multicancer Screening Market, $Billion, 2021-2032
  • Figure 35: Asia-Pacific Multicancer Screening Market Share (by Country), $Million, 2021-2032
  • Figure 36: China Multicancer Screening Market, $Million, 2021-2032
  • Figure 37: Japan Multicancer Screening Market, $Million, 2021-2032
  • Figure 38: India Multicancer Screening Market, $Million, 2021-2032
  • Figure 39: Australia Multicancer Screening Market, $Million, 2021-2032
  • Figure 40: South Korea Multicancer Screening Market, $Million, 2021-2032
  • Figure 41: Rest-of-Asia-Pacific Multicancer Screening Market, $Million, 2021-2032
  • Figure 42: Multicancer Screening Market, Total Number of Companies Profiled
  • Figure 43: Multicancer Screening Market: Value Chain
  • Figure 44: Burning Rock DX: Product Portfolio
  • Figure 45: Genecast Biotechnology Co., Ltd: Product Portfolio
  • Figure 46: Konica Minolta, Inc. (Ambry Genetics.): Product Portfolio
  • Figure 47: Konica Minolta, Inc. (Ambry Genetics.): Overall Financials, $Million, 2019-2021
  • Figure 48: Konica Minolta, Inc. (Ambry Genetics.): Revenue (by Segment), $Million, 2019-2021
  • Figure 49: Konica Minolta, Inc. (Ambry Genetics.): Revenue (by Region), $Million, 2019-2021
  • Figure 50: Konica Minolta, Inc. (Ambry Genetics.): R&D Expenditure, $Million, 2019-2021

List of Tables

  • Table 1: Impact Analysis of Market Drivers, Challenges, and Opportunities on the Asia-Pacific Multicancer Screening Market
  • Table 2: Technological Trends in Asia-Pacific Multicancer Screening Market
  • Table 3: Average Prices of Multicancer Screening Kits Calculation
  • Table 4: Likert Scale
  • Table 5: Impact Analysis of Market Drivers
  • Table 6: Impact Analysis of Market Challenges
  • Table 7: Five-Year Survival Rates for Different Cancers at Different Stages
  • Table 8: Top Multicancer Screening Tests and Their Costs ($)
  • Table 9: Asia-Pacific Multicancer Screening Market, Pipeline Tests
  • Table 10: Cancers and Their Most Common Biomarker Tests
目次
Product Code: BHP1532SS

“The Asia-Pacific Multicancer Screening Market Expected to Reach $1.40 Billion by 2032.”

Introduction to Asia-Pacific (APAC) Multicancer Screening Market

As of 2022, the Asia-Pacific multicancer screening market was valued at $0.27 billion and is expected to attain a value of $1.40 billion by 2032. The rising incidence of cancer and growing use of liquid biopsy testing are anticipated to fuel market expansion for multicancer screening in Asia-Pacific.

KEY MARKET STATISTICS
Forecast Period2023 - 2032
2023 Evaluation$0.32 Billion
2032 Forecast$1.40 Billion
CAGR17.6%

Market Introduction

The market for multicancer screening in Asia-Pacific (APAC) is expected to develop significantly as the area concentrates on improving healthcare infrastructure and tackling the increased incidence of different malignancies. The practice of multicancer screening, which is the simultaneous detection of numerous cancer types by sophisticated diagnostic techniques, is becoming more and more popular throughout Asia-Pacific as people become more aware of the critical role that early detection plays in enhancing treatment outcomes. The market is being pushed by increasing initiatives for cancer prevention and control, an aging population, and technical breakthroughs in screening technologies. The multicancer screening market is growing as a result of governments and healthcare organizations in the Asia-Pacific area placing a strong emphasis on the adoption of comprehensive cancer screening programs. The market for APAC multicancer screening is expected to grow as demand increases for more accessible and precise cancer diagnosis.

Market Segmentation

Segmentation 1: by Country

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest-of-Asia-Pacific

In 2021, China was the leading contributor to the Asia-Pacific multicancer screening market, with a market share of 32.64%. Japan is the second-largest contributor to the Asia-Pacific multicancer screening market.

How can this report add value to an organization?

Product/Innovation Strategy: The report considers multicancer screening kit/panel and assay product-based companies. The industry is seeing constant development and product launches with new and innovative upgrades. Additionally, new discoveries of specific biomarkers related to various cancer types are increasing researchers' trust in multicancer sequencing.

Growth/Marketing Strategy: The key components in multicancer screening are the kits and the related technologies for sample analysis. The advancements in new analysis methods like liquid biopsy are influencing the growth of this market. Additionally, the discovery of biomarkers and other genes for various diseases is helping panel manufacturers curate precise kits and assays for multicancer screening of various cancer types.

Competitive Strategy: The key players in the Asia-Pacific multicancer screening market have been analyzed and profiled in the study, consisting of most product-based companies, as well as a few emerging companies. Moreover, a detailed competitive benchmarking of the players operating in the Asia-Pacific multicancer screening market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts, analyzing company coverage, product portfolio, and market penetration.

Some of the prominent names established in this market are:

  • Burning Rock DX
  • Genecast Biotechnology Co., Ltd.
  • Konica Minolta, Inc. (Ambry Genetics.)

Table of Contents

1 Markets

  • 1.1 Product Definition
  • 1.2 Inclusion and Exclusion Criteria
  • 1.3 Market Scope
    • 1.3.1 Scope of the Study
    • 1.3.2 Key Questions Answered in the Report
  • 1.4 Research Methodology
    • 1.4.1 Asia-Pacific Multicancer Screening Market: Research Methodology
    • 1.4.2 Data Sources
    • 1.4.3 Market Estimation Model
    • 1.4.4 Criteria for Company Profiling

2 Market Overview

  • 2.1 Market Overview
  • 2.2 Multicancer Screening Workflow Analysis
  • 2.3 Market Footprint and Growth Potential
  • 2.4 Future Potential
  • 2.5 COVID-19 Impact on the Market

3 Industry Insights

  • 3.1 Patent Analysis
    • 3.1.1 Patent Filing Trend
    • 3.1.2 Patent Analysis (by Country)
    • 3.1.3 Patent Analysis (by Region)
  • 3.2 Reimbursement Scenario
  • 3.3 Supply Chain Analysis
  • 3.4 Pricing Analysis (by Test Type)

4 Market Dynamics

  • 4.1 Overview
  • 4.2 Impact Analysis
  • 4.3 Market Drivers
    • 4.3.1 Early Detection of Cancer Leads to Higher Survival Chances and Better Treatment
    • 4.3.2 Increasing Popularity of Liquid Biopsy Leading to Easier Screening
    • 4.3.3 Reduced Treatment Cost Due to Earlier Cancer Detection
  • 4.4 Market Challenges
    • 4.4.1 Lack of Awareness about the Multicancer Screening Tests
    • 4.4.2 Too Costly to be Used as Preventive Care
  • 4.5 Market Opportunities
    • 4.5.1 Robust Pipeline of Multicancer Screening Tests Poised to Revolutionize Cancer Diagnosis
    • 4.5.2 New Biomarkers being Discovered Regularly

5 Competitive Landscape

  • 5.1 Key Strategies and Developments
    • 5.1.1 Mergers and Acquisitions
    • 5.1.2 Synergistic Activities
    • 5.1.3 Product Launches and Upgradations
    • 5.1.4 Funding and Expansion
  • 5.2 Market Share Analysis (2022)
  • 5.3 Growth-Share Analysis (2022)
    • 5.3.1 Growth-Share Analysis (by Technology)

6 Asia-Pacific

  • 6.1 Overview
  • 6.2 Asia-Pacific
    • 6.2.1 China
    • 6.2.2 Japan
    • 6.2.3 India
    • 6.2.4 Australia
    • 6.2.5 South Korea
    • 6.2.6 Rest-of-Asia-Pacific

7 Markets - Company Profiles

  • 7.1 Overview
  • 7.2 Market Value Chain of Multicancer Screening Market
  • 7.3 Multicancer Screening Ecosystem Active Players
  • 7.4 Burning Rock DX
    • 7.4.1 Company Overview
    • 7.4.2 Role of Burning Rock DX in the Asia-Pacific Multicancer Screening Market
    • 7.4.3 Key Competitors of the Company
    • 7.4.4 Business Strategies
    • 7.4.5 Analyst Perspective
  • 7.5 Genecast Biotechnology Co., Ltd
    • 7.5.1 Company Overview
    • 7.5.2 Role of Genecast Biotechnology Co., Ltd in the Asia-Pacific Multicancer Screening Market
    • 7.5.3 Key Competitors of the Company
    • 7.5.4 Analyst Perspective
  • 7.6 Konica Minolta, Inc. (Ambry Genetics.)
    • 7.6.1 Company Overview
    • 7.6.2 Role of Konica Minolta, Inc. (Ambry Genetics.) in the Asia-Pacific Multicancer Screening Market
    • 7.6.3 Key Competitors of the Company
    • 7.6.4 Financials
    • 7.6.5 Analyst Perspective